
Danaher, Moderna, and ImmunityBio are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that research, develop, and commercialize biological and medical products—such as drugs, vaccines, diagnostics, and gene therapies—and whose valuations depend heavily on clinical trial results, regulatory approvals, and intellectual property. For investors, they tend to be higher-risk and higher-reward than many other sectors because of long R&D timelines, large development costs, and binary outcomes from trials and regulatory decisions. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read Our Latest Research Report on MRNA
ImmunityBio (IBRX)
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Read Our Latest Research Report on IBRX
Read More
- MarketBeat’s Top Five Stocks to Own in March 2026
- 5 Stocks Racing Ahead as AI Supercharges Robotics
- Super Micro: Why the Shadow of NVIDIA Is a Profitable Place to Be
- Meta Is Bringing Back Stablecoin Payments—This Time the Conditions Are Different
- Defense Stocks Are Soaring—AeroVironment’s Earnings Could Close the Gap
- As Investors Flee U.S. Equities, This Global ETF Is Outperforming
